Valtruis, an investment company, led a $33m Series B round in Atropos Health, a healthcare firm, with participation from Cencora Ventures, McKesson Ventures, Merck Global Health Innovation Fund, Breyer Capital, Emerson Collective and Presidio Ventures. “This funding round, which includes multiple major strategic stakeholders in the healthcare ecosystem, is validation that our platform is rapidly becoming the standard not only for automation and user experience, but also as the trusted quality layer between healthcare data and the critical evidence needed to better inform patient care, research, and policy,” Brigham Hyde, Atropos Health CEO and Co-Founder.